Evidence map›Paper›PMID 42776261›Full record

ArticleWorld journal of urology2026

Factors associated with long-distance travel among patients undergoing radical prostatectomy at a German high-volume tertiary prostate cancer centre.

Sami-Ramzi Leyh-Bannurah, Lars Budäus, Armin Soave, Su Oh-Hohenhorst, Clemens Rosenbaum, Christian Wagner, Fabian Falkenbach, Theodoros Karagiotis, Nikolaos Liakos, Okyaz Eminaga and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Sami-Ramzi Leyh-BannurahDepartment of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. s.bannurah@googlemail.com.ORCID https://orcid.org/0000-0002-6156-2117
Lars BudäusDepartment of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Armin SoaveDepartment of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Su Oh-HohenhorstDepartment of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Clemens RosenbaumAsklepios Paulinen Klinik, Wiesbaden, Germany.
Christian WagnerProstate Center Northwest, Department of Urology, Pediatric Urology and Uro-Oncology, St. Antonius-Hospital, Gronau, Germany.
Fabian FalkenbachDepartment of Urology, Heidelberg University Hospital, Heidelberg, Germany.
Theodoros KaragiotisSecond Department of Urology, Medical School, Sismanoglio Hospital, National and Kapodistrian University of Athens, Sismanogliou 37, Athens, Greece.
Nikolaos LiakosDepartment of Urology, University of Freiburg, Freiburg im Breisgau, Germany.
Okyaz EminagaAI Vobis, Palo Alto and Department of Anesthesia, Stanford University School of Medicine, Palo Alto, CA, USA.
Mahmoud FarzatDepartment of Urology, Pediatric Urology, and Andrology, Justus-Liebig University of Giessen, Giessen, Germany.
Zhe TianCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada.
Georg SalomonDepartment of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Thomas SteuberDepartment of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Felix PreisserDepartment of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Alexander HaeseMartini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Tobias MaurerDepartment of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Margit FischDepartment of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Markus GraefenMartini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Frank Schiemann *Faculty of Social Sciences, Economics and Business Administration, University of Bamberg, Bamberg, Germany.
Mykyta Kachanov *Department of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate determinants of long-distance travel for radical prostatectomy (RP) to a German high-volume tertiary centre.

methodsA total of 15,727 patients underwent RP at our high-volume tertiary centre (2019-2025). Distances from residential postal codes to our centre were computed using the Google Maps Directions API. Long-distance travel was defined a priori as > 300 km. Multivariable logistic regression analysis (MVA) was used to identify factors associated with this outcome and were complemented with sensitivity analyses that evaluated alternative distance thresholds (100-400 km), and a continuous log-transformed distance model.

resultsIn our cohort, 10,672 (68%) patients travelled ≤ 300 km. Those who travelled > 300 km were younger (median 64 vs.65 years), more often underwent RARP (80% vs.64%), and were more likely to have private insurance (66% vs.43%) (all p < 0.001). In MVA, younger age, private insurance, RARP, and residence in Towns and Villages (DEGURBA stratification) were independently associated with long-distance travel. These socio-demographic predictors remained highly consistent and significant across all alternative thresholds and the continuous model. Interestingly, greater distance to nearest certified PCa centre reduced the odds of travelling even farther to our centre. Disease-related variables such as EAU risk group and baseline erectile function did not achieve independent predictor status for long-distance travel.

conclusionsNearly one-third of patients bypassed nearby certified providers and travelled > 300 km for RP. Long-distance travel was associated primarily by non-disease-related factors, rather than disease-related, that might affect oncological or functional outcomes. Transparent outcome reporting and counselling are needed to align travel decisions with objective quality metrics.

Indexed as

Health Services AccessibilityProstatectomyProstatic NeoplasmsTravelAgedGermanyHospitals, High-VolumeHumansMaleMiddle AgedTertiary Care CentersHealth services accessibilityPatient mobilityProstate cancerProstatectomyRobot-assisted radical prostatectomyTravel distance

Identifiers

PMID42776261

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.